Divi's Lab

₹3795 5.5 | 0.1%

WEBSITE BSE:532488 NSE : DIVI'S LAB. 10 May, 09:31

Market Cap ₹100745 Cr.

Stock P/E 72.8

P/B 7.7

Current Price ₹3795

Book Value ₹ 491

Face Value 2

52W High ₹4104

Dividend Yield 0.79%

52W Low ₹ 3050.2

Edit Ratio

Divi's Lab Research see more...

Overview Inc. Year: 1990Industry: Pharmaceuticals & Drugs

Divi's Laboratories Ltd manufactures Active Pharma Ingredients (APIs) and intermediates. The organization in a matter of short time multiplied their breadth of operations to offer whole turnkey solutions to the domestic Indian pharmaceutical enterprise.They are actively concerned in growing trade, patent non-infringing approaches for APIs, for the inventors to control late life cycle and leading customary drug producers.The company's product variety includes Bupropion Hbr,Bupropion HCL,Capecitabine,Carbidopa,Desloratadine,Dexlansoprazole /(R)-Lansoprazole, Irbesartan, Levodopa, Niacin, Sibutramine HCL, Valacyclovir HCL, Valsartan, Venlafaxine HCL, VerapamiL HCL, Vigabatrin, Zolpidem Tartrate ,and so forth.

Divi's Lab Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Divi's Lab Quarterly Results

#(Fig in Cr.)	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
Net Sales	1988	2493	2518	2255	1855	1708	1951	1778	1909	1855
Other Income	19	17	52	88	80	113	66	81	86	95
Total Income	2007	2510	2571	2343	1935	1821	2017	1859	1995	1950
Total Expenditure	1169	1396	1414	1407	1234	1299	1463	1274	1430	1366
Operating Profit	837	1114	1157	936	701	522	554	585	565	584
Interest	0	0	0	0	0	0	0	0	1	0
Depreciation	77	80	81	84	86	87	87	93	95	95
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	760	1034	1076	852	615	435	466	492	469	489
Provision for Tax	153	131	181	150	122	129	146	136	121	131
Profit After Tax	606	902	895	702	493	306	321	356	348	358
Adjustments	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	606	902	895	702	493	306	321	356	348	358
Adjusted Earnings Per Share	22.8	34	33.7	26.4	18.6	11.5	12.1	13.4	13.1	13.5

Divi's Lab Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	2145	2532	3115	3776	4064	3891	4946	5394	6969	8960	7768	7493
Other Income	45	71	45	97	75	113	156	190	63	116	345	328
Total Income	2190	2603	3160	3874	4139	4005	5102	5584	7032	9076	8112	7821
Total Expenditure	1329	1517	1949	2358	2617	2629	3073	3571	4108	5079	5398	5533
Operating Profit	861	1086	1211	1516	1522	1376	2029	2013	2924	3997	2714	2288
Interest	3	3	3	5	3	2	5	7	2	2	2	1
Depreciation	77	92	136	118	123	142	169	186	256	312	343	370
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	781	991	1072	1393	1395	1231	1855	1819	2666	3684	2369	1916
Provision for Tax	179	218	221	267	335	354	502	443	682	723	545	534
Profit After Tax	602	773	852	1126	1060	877	1353	1377	1984	2960	1823	1383
Adjustments	0	0	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	602	773	852	1126	1060	877	1353	1377	1984	2960	1823	1383
Adjusted Earnings Per Share	22.7	29.1	32.1	42.4	39.9	33	51	51.9	74.8	111.5	68.7	52.1

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	-13%	13%	15%	14%
Operating Profit CAGR	-32%	10%	15%	12%
PAT CAGR	-38%	10%	16%	12%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	11%	-3%	18%	19%
ROE Average	15%	22%	21%	23%
ROCE Average	19%	29%	28%	30%

Divi's Lab Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	2501	2963	3495	4293	5357	5925	6957	7310	9295	11728	12767
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	2	2	1	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	468	648	841	85	1412	1769	991	295	364	437	556
Total Current Liabilities	554	627	776	520	659	653	847	1821	1728	2454	1533
Total Liabilities	3525	4241	5112	4898	7429	8347	8795	9425	11387	14619	14857
Fixed Assets	909	1222	1309	1439	1559	1996	2088	2782	3704	4325	4723
Other Non-Current Assets	752	763	1031	432	1859	1816	2057	1070	892	684	390
Total Current Assets	1864	2256	2772	3027	4011	4535	4650	5574	6791	9610	9744
Total Assets	3525	4241	5112	4898	7429	8347	8795	9425	11387	14619	14857

Divi's Lab Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	17	12	15	18	-17	-4	-21	2	43	2030	1215
Cash Flow from Operating Activities	480	557	826	1038	1150	776	954	1216	1947	1912	2460
Cash Flow from Investing Activities	-255	-305	-521	-406	-1140	-478	-685	-83	75	-2195	-2708
Cash Flow from Financing Activities	-231	-248	-303	-631	2	-314	-246	-1091	-35	-532	-797
Net Cash Inflow / Outflow	-5	3	3	0	13	-17	23	41	1987	-816	-1045
Closing Cash & Cash Equivalent	12	15	18	18	-4	-21	2	43	2030	1215	170

Divi's Lab Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	22.68	29.13	32.08	42.41	39.95	33.04	50.96	51.86	74.75	111.53	68.69
CEPS(Rs)	25.58	32.6	37.2	46.86	44.59	38.41	57.32	58.87	84.38	123.26	81.62
DPS(Rs)	15	20	20	10	10	10	16	16	20	30	30
Book NAV/Share(Rs)	94.2	111.63	131.67	161.73	201.82	223.2	262.09	275.38	350.15	441.82	480.96
Core EBITDA Margin(%)	37.77	39.81	37.12	37.28	35.24	32.27	37.6	33.41	40.92	43.18	30.3
EBIT Margin(%)	36.28	38.97	34.21	36.73	34.06	31.53	37.33	33.48	38.16	41	30.32
Pre Tax Margin(%)	36.17	38.85	34.12	36.61	33.98	31.47	37.24	33.35	38.13	40.98	30.29
PAT Margin (%)	27.87	30.32	27.1	29.59	25.82	22.41	27.15	25.23	28.38	32.94	23.32
Cash Profit Margin (%)	31.43	33.93	31.43	32.69	28.83	26.06	30.54	28.64	32.04	36.4	27.71
ROA(%)	19.17	19.92	18.21	22.49	17.21	11.12	15.78	15.11	19.07	22.77	12.37
ROE(%)	25.99	28.31	26.37	28.91	21.98	15.55	21	19.3	23.9	28.16	14.89
ROCE(%)	33.21	36.04	33.06	35.57	28.75	21.68	28.5	25.36	32.07	35.06	19.36
Receivable days	85.08	88.42	85.12	77.83	79.19	89.33	79.78	86.18	80.66	83.26	98.41
Inventory Days	127.96	126.52	121.69	113.7	112.34	124.56	114.41	121.62	104.66	100.99	136.05
Payable days	73.12	62.32	56.95	55.71	80.72	101.95	90.34	93.73	106.32	95.88	93.12
PER(x)	21.69	23.5	27.9	23.23	15.62	32.98	33.42	38.33	48.56	39.49	41.14
Price/Book(x)	5.22	6.13	6.8	6.09	3.09	4.88	6.5	7.22	10.37	9.97	5.88
Dividend Yield(%)	1.52	1.46	1.12	1.02	1.6	0.92	0.94	0.81	0.55	0.68	1.06
EV/Net Sales(x)	6.08	7.17	7.62	6.92	4.07	7.42	9.14	9.76	13.52	12.73	9.11
EV/Core EBITDA(x)	15.16	16.71	19.59	17.23	10.86	20.98	22.28	26.17	32.22	28.54	26.09
Net Sales Growth(%)	15.07	18.06	23.02	21.23	7.63	-4.25	27.1	9.06	29.2	28.56	-13.31
EBIT Growth(%)	14.39	26.8	8.16	30.01	0.08	-11.8	50.75	-1.78	46.07	38.13	-35.68
PAT Growth(%)	12.89	28.46	10.11	32.21	-5.81	-17.3	54.24	1.76	44.15	49.19	-38.41
EPS Growth(%)	12.89	28.46	10.11	32.21	-5.8	-17.3	54.24	1.76	44.15	49.19	-38.41
Debt/Equity(x)	0.01	0.01	0.01	0.01	0.01	0.01	0.02	0	0	0	0
Current Ratio(x)	3.36	3.6	3.57	5.83	6.08	6.94	5.49	3.06	3.93	3.92	6.36
Quick Ratio(x)	1.85	2.11	2.08	3.5	4.08	4.87	3.4	2.04	2.69	2.76	4.4
Interest Cover(x)	302.96	336.24	373.59	294.75	416.28	520.55	397.38	255.83	1270.54	1842.75	1209.48
Total Debt/Mcap(x)	0	0	0	0	0	0	0	0	0	0	0

Divi's Lab Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	51.95	51.94	51.94	51.94	51.94	51.94	51.93	51.93	51.92	51.92
FII	19.3	18.45	16.52	15.4	15.14	14.67	14.7	14.6	14.86	14.68
DII	17.73	18.32	19.98	20.78	20.67	21.08	21.23	21.75	21.88	22.21
Public	11.02	11.28	11.56	11.88	12.24	12.31	12.14	11.73	11.34	11.19
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	13.79	13.79	13.79	13.79	13.79	13.79	13.79	13.79	13.78	13.78
FII	5.12	4.9	4.39	4.09	4.02	3.89	3.9	3.88	3.94	3.9
DII	4.71	4.86	5.3	5.52	5.49	5.59	5.64	5.77	5.81	5.9
Public	2.93	3	3.07	3.15	3.25	3.27	3.22	3.11	3.01	2.97
Others	0	0	0	0	0	0	0	0	0	0
Total	26.55	26.55	26.55	26.55	26.55	26.55	26.55	26.55	26.55	26.55

Pros

Company has a good return on equity (ROE) track record: 3 Years ROE 22%
Debtor days have improved from 95.88 to 93.12days.
Company is almost debt free.

Cons

Stock is trading at 7.7 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Divi's Lab News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Divi's Lab

Add Watchlist

Divi's Lab Research see more...

Overview Inc. Year: 1990Industry: Pharmaceuticals & Drugs

Divi's Lab Share Price

Alert Data

Quarterly Price

Peer Comparison

Divi's Lab Quarterly Results

Divi's Lab Profit & Loss

Growth Rates

Divi's Lab Balance Sheet

Divi's Lab Cash Flow

Divi's Lab Ratios

Divi's Lab Shareholding Pattern

Divi's Lab News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!